The pieces on Danaher & Bayer were particularly interesting. Change management is generally very challenging to implement. In Bayer’s case, you couldn’t just run the typical PE playbook of reducing costs/management as they need to retain the creative component of the company. In many ways the company exemplifies the challenges of being a mid-size player (especially in pharma)-too big to be agile and too small to achieve real scale (plus the Monsanto overhang).
The pieces on Danaher & Bayer were particularly interesting. Change management is generally very challenging to implement. In Bayer’s case, you couldn’t just run the typical PE playbook of reducing costs/management as they need to retain the creative component of the company. In many ways the company exemplifies the challenges of being a mid-size player (especially in pharma)-too big to be agile and too small to achieve real scale (plus the Monsanto overhang).